Osborne Clarke celebrates a successful year of Life Sciences and Healthcare corporate deals

Osborne Clarke has closed another year of high profile life sciences and healthcare corporate transactions. 

Partner Matthew Edwards said: "We've enjoyed a stellar year working alongside our clients on a number of hugely significant transactions. We are very much looking forward to continuing to build on our success in 2022." 

Here are a selection of the deals the team has been involved with during 2021:

•    Advising Turbine on a €5.7M fund raising round.

•    Advising the management team of Lucid Group, LDC and other shareholders on its partnership with new investor Intermediate Capital Group. 

•    Advising the shareholders of Fortius Group Limited on its sale of the company, to Affidea Group.

•    Advising Amphista Therapeutics on its $53M Series B financing round.

•    Advising NeRRe Therapeutics on its £20M Series B2 financing round. 

•    Advising Creo Medical Group on a £36M fundraising. 

•    Advising Tiger Global Management on its lead investment in Lifebit Biotech's $60M Series B funding round. 

•    Advising AviadoBio on its $80M Series A financing round.

•    Advising Grifols on its €1.1BN Biotest acquisition. 

•    Advising Uniphar on its acquisitions of E4H and Devonshire Healthcare Services. 

•    Advising Science Creates Ventures on five investments, including investments into Forefront RF and CytoSeek. 

•    Advising RHYTHM AI on its £2.15M seed financing round. 

•    Advising Nufomix on its fundraising. 

•    Advising Oxular on its £27M financing.